PDLIM2 and breast carcinoma: The treatment of breast cancer cells with 5-aza-2′-deoxycytidine reversed the methylation of the PDLIM2 promoter, restored PDLIM2 expression, and suppressed tumorigenicity of human breast cancer cells [25].